[illegible]

[illegible]: [illegible]

[illegible]-[illegible] (bk-PMMA) - [illegible]

[illegible]

⚠ [illegible] - [illegible] | [illegible]: [illegible]

[illegible]

[illegible] - [illegible]: [illegible]

[illegible]

[illegible]:

- [illegible] – [illegible]
- [illegible] - [illegible]
- [illegible]— [illegible]

[illegible]

⚠ [illegible]

[illegible]

[illegible] 6 — [illegible] [illegible] [illegible] [illegible]

[illegible] - [illegible] [illegible] [illegible] [illegible]

Methedrone [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (MAOI) [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] — [illegible]?

[illegible] "[illegible]" [illegible] '[illegible]' [illegible] PAWS ([illegible]-[illegible]) [illegible] ([illegible])—[illegible]

[illegible]

[illegible]

[illegible] — [illegible]

- [illegible]
- [illegible]
- [illegible] PAWS (Post-Acute Withdrawal Syndrome) [illegible]
- [illegible] ([illegible]), [illegible]—[illegible]

[illegible] — [illegible]

[illegible] / [illegible]	[illegible]
CYP2D6	[illegible]
SLC6A4 (5-HTTLPR)	[illegible]
MAOA (uVNTR)	[illegible]—[illegible] MAOI [illegible]—[illegible]
COMT (Val158Met)	[illegible]

[illegible] / [illegible]	[illegible] [illegible]
	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

⚠ [illegible]

[illegible] [illegible] [illegible] CYP2D6 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□.□ - □□□□□□□ □ benzodiazepines

□□□□□□□ □□ □□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□ □□□□□□ □□ □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□ □□□□, □□□□ □□□□□ □□□□ □□□ □□□□□□ □□□□□ □□□□□□ □□□ □□□□□□□ □□□ □□□□□□□ □□□□ □□□ □□□□□ □□□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□□□□□□ □ □□□, □□□□ □□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□ □□□□□□□□□□—□□□□□ □□□ □□□□□□□□□□□□□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□□□, □□□ □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□, □ □□□□□ □□□□□□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□ □□□ □□ □□□□□□ □□□□ □□□□, □□ □□□□□□□□□□ "□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□" □□□□ □□□□□□□□□□□□□

□.□ — □□□□□□ (□□□□□□□□□□ □□ □□□□□)□

□ □□□□□□□□ □□□□□□□□□□ □□□□□□

□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□ MAOI (□□□□□ □□□□□□□□□, □□□□□□□□□□□□□□□□□□, □□ □□□□□□□□□□) □□□ □□□□□□ □□□□□□ □□□□□ □□□□□ □□□□ □□□□□□ □ □□□□□□ □□□□ □□□□ □□□□□□ □□□ □□□ □□ □□□□□□□□ □□□□ □□□□□ □□□, □□ □□□□, □□□□ □□□ □□□□□□ □□□□□, □□ □□□□ □□□ □□□□□□□□ □□□□-□□□□□□□□□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□□ □ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□ □□□□□□□□□, □□□□□ □□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□ □□□ □□□ □□□□□□ □□□□□□□□□ □□□□□□ □□□□□□□□□□

Section 7 — Use Pattern Classification

□□□□□□□□□□□ □□□□□□ □□□□ □□□□□□ □ □□□□□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□ □□□□□ □□□□□□□□□ □□□□ □□□□□□ □□□□□—□□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□□□, □□ □□□□ □ □□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□ □□□□ □□□ □□□□□□□□ □□□□ □□□□□□□□

□□□□	□□□□□□□	□□ □□□□□□ □□ □□□□□□□ □□□□□□
1 — □□□□□□□□□□ □□	□□ □□ □□□ □□□ □□□□□ □□□□□□, □□□□ □□□□ □□□□□□□□□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□	□□□ □□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□ □□□ □□□, □□□□□□□□□□□ □□□□□□□ □□□□□□□□□; □□□□□□, □□□□□□ □□□□□□ □□□□□ □□□□□□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□
□ - □□□□□□□□□□ □	□□□–□□□□□ □□□□□□□□□□ □□□□ □□□□□, □□□□□□□□□□ □□□□□□□ □□ □□□□□□□□□ □□□□□□□	□□□ □□ □ □□□□□□□ □□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□
□ - □□□□□□□/□□□ □□	□□□□□ □□□□□□□ □□□ □□□□□□□ □□ □□□□ □□□□□□□□□□ □□□□ □□	□□□□□□ □□□, □□□□□ □□□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□□□ □□□, □□□□□□□□ □□□ □□□□ □□□□□□□□ □□
□ - □□□□□□□/□□□ -□□□□□ □□□□□□	□□□□ □□□ □□□□□□ □□□□□, □□□□□□ □□□□ □□□□□□□ □□□□□□□□□, GHB, □□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□	□□□□□□□□ □□□□□□□□□□□□ □□□□ □□□□□□ □□□□□□□ □; □□□□□□□□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□□□

□□□□ □ - □□□□□□ □□□□□□□ □□□□□□□□

Okay, I understand. This section emphasizes that because there are no standard treatments or FDA-approved medications for methedrone/synthetic cathinone withdrawal, and due to the lack of specific detox protocols, the physician's comprehensive

understanding of the individual's overall health (as detailed in Section 6) is crucial for determining a safe and appropriate care plan.

⚠ [illegible]

Okay, I understand. You want me to provide safety information related to methedrone (or its discontinuation) using only the following terms, and without softening the language:

*   **not optional**
*   **mandatory**
*   **do not run this module**
*   **medical help is not failure**

Here's how I can use those terms in a safety context related to methedrone discontinuation:

Safety Guidance Regarding Methedrone Discontinuation:

[illegible]:

- [illegible]
- [illegible]
- [illegible]
- [illegible]

[illegible]

[illegible]

[illegible]

- 5-MTHF ([illegible]) – [illegible]
- [illegible]
- [illegible]-3 ([illegible]) - [illegible]
- [illegible]

[illegible] -

[illegible]

[illegible] 6 - [illegible]

- [illegible]
- [illegible]
- [illegible]
- [illegible]

[illegible] 66 - [illegible]

[illegible]

This is a good start to outlining potential adverse effects and when to seek medical attention related to methedrone use. Here's a breakdown of why it's helpful and some suggestions for improvement:

Strengths:

* **Clear Differentiation:** You clearly distinguish between expected side effects (low mood, fatigue, sleep disruption) and potentially dangerous ones requiring immediate attention.
* **Specificity:** You list specific symptoms that should raise concern, including cardiovascular issues (rapid heartbeat, high blood pressure

[illegible] 67 - [illegible]

[illegible]	[illegible]
[illegible]	Recovery Kernel – [illegible] [illegible] (Recovery Kernel)
[illegible]	Recovery Kernel – [illegible] [illegible] [illegible]: [illegible]
GHB/GBL/1,4-BD [illegible]	Recovery Kernel - GHB [illegible] [illegible]
[illegible]	Recovery Kernel - [illegible]: benzodiazepine [illegible]
[illegible]	Recovery Kernel - [illegible] [illegible]
[illegible] / [illegible]	Recovery Kernel - [illegible] [illegible]
[illegible]	Recovery Kernel - [illegible] [illegible]

[illegible] 68 - [illegible]

[illegible]

This passage highlights the unique challenges of discontinuing methedrone compared to other medications. Here's a breakdown:

*   **Severity of Withdrawal:** While the withdrawal from methedrone might be severe, it's not necessarily *more* severe than withdrawals from other substances. The key difference lies in how it's managed.
*   **Importance of Complete Disclosure:** Successful and safe discontinuation hinges on an open and honest conversation with a physician about all medications and substances being taken, both [illegible]

[illegible] -- [illegible]: [illegible]

[illegible] -- [illegible] -- [illegible]

Crisis Resources: 988 (Suicide & Crisis Lifeline, call or text) | Crisis Text: HOME to 741741 | SAMHSA: 1-800-662-4357